Previous 10 | Next 10 |
Atossa Therapeutics press release (NASDAQ:ATOS): FY GAAP EPS of -$0.18. Shares +2.5%. As of December 31, 2021, we had cash, cash equivalents and restricted cash of $136 million. For further details see: Atossa Therapeutics GAAP EPS of -$0.18
SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial resu...
Gainers: IceCure Medical (NASDAQ:ICCM) +16%. Atossa Therapeutics (NASDAQ:ATOS) +15%. G Medical Innovations (NASDAQ:GMVD) +11%. Exscientia (NASDAQ:EXAI) +10%. Immix Biopharma (NASDAQ:IMMX) +10%. Losers: Dermata Therapeutics (NASDAQ:DRMA) -...
SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and CO...
SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and CO...
SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COV...
Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur The BANAL-236 coronavirus violates 40 years of coronavirus research to infect human cells PR Newswire SEATTLE , Dec. 16, 2021 /P...
Today, we take our first in-depth look at a small developmental company called Atossa Therapeutics. The company is targeting breast cancer and Covid-19 within its pipeline. A full investment analysis on Atossa Therapeutics is presented in the paragraphs below. For further de...
Are These Penny Stocks on Your December Watchlist? In December 2021, there is a sizable amount of bullish sentiment with penny stocks. As a result of the sheer number of factors impacting the stock market, those who know how to trade penny stocks can take advantage. Right now, the m...
SEATTLE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that it ...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa’s ...